Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “hydrogen”

65 pharma patents match "hydrogen" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 65
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 65 pharmaceutical patents matching "hydrogen" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

65 results for “hydrogen” · 30,257 patents in full index Clear search

  1. US 20260125398

    5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS

    AMGEN INC [US] · Granted May 7, 2026 · Expires May 2, 2046

    granted

  2. US 12384753

    17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted

  3. US 12383535

    Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted

  4. US 12365653

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted

  5. US 12336982

    Compositions and methods of modulating short-chain dehydrogenase activity

    The Board of Regents of the University of Texas System · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted

  6. US 12257132

    Hydrogen-delivering system for a bodily orifice

    H2 Universe LLC · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted

  7. US 12233051

    Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted

  8. US 12209073

    Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

    KIORA PHARMACEUTICALS GmbH · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted

  9. US 12162877

    Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation

    DRUG DISCOVERY AND CLINIC S.R.L. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted

  10. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted

  11. US 12054475

    Substituted heterocycles as aldehyde dehydrogenase inhibitors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted

  12. US 12017030

    Hydrogen-enhanced transdermal system

    H2 Universe LLC · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted

  13. US 11925623

    Methods for the treatment of conditions related to hydrogen sulfide

    Regents of the University of Minnesota · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted

  14. US 11897845

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted

  15. US 11752138

    Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted

  16. US 11718589

    Compositions and methods of modulating short-chain dehydrogenase

    The Board of Regents of the University of Texas System · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted

  17. US 11629349

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted

  18. US 11549112

    RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted

  19. US 11426420

    Inhibitors of short-chain dehydrogenase activity for treating coronary disorders

    The Board of Regents of the University of Texas System · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  20. US 11364261

    Alleviating common cold and influenza symptoms with molecular hydrogen

    H2 Universe LLC · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted

  21. US 11326166

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  22. US 11319539

    Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 3, 2022 · Expires Apr 28, 2042

    granted

  23. US 11273431

    Biologically applicable water-soluble heterogeneous catalysts for para-hydrogen induced polarization

    The Regents of the University of California · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  24. US 11247971

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.